Inhibitory effects of a neurokinin-1 receptor antagonist on postoperative peritoneal adhesion formation.
Intra-abdominal adhesions are a costly, long-term sequela of abdominal surgeries. They occur in up to 94% of patients following abdominal operation and cause significant postoperative morbidity including difficult reoperative surgeries, small bowel obstructions, and infertility. The pathophysiology of adhesion formation remains poorly defined, and a uniformly effective method of adhesion prevention does not exist. Research focused on understanding the mechanisms underlying adhesion formation is essential for the development of safe and effective therapeutic approaches to adhesion prevention. The proinflammatory peptide substance P (SP), known to participate in inflammatory and wound-healing events, may contribute to the early processes of adhesion formation. SP is the most widely studied ligand of the neurokinin-1 receptor (NK-1R), and we have determined in a rat model that intraoperative administration of an NK-1R antagonist, CJ-12-255 (Pfizer), that blocks ligand binding to the NK-1R, significantly reduces adhesion formation. It also has been determined that animals administered the NK-1R antagonist intraperitoneally have increased peritoneal fibrinolytic and matrix metalloproteinase activities, and reduced levels of oxidative stress postoperatively, all of which may contribute to the observed reduction in adhesion formation. Studies suggest that intra-abdominal adhesion formation begins within hours of surgery and that the regulation of fibrin deposition, and degradation is of key importance. A pharmacologic agent, such as an NK-1R antagonist, administered at the time of surgery that could augment postoperative peritoneal fibrinolytic activity without compromising wound healing, would be a beneficial tool in the prevention of postoperative adhesions.
Reed
Karen L
KL
Department of Surgery, Boston University School of Medicine, Boston, MA, USA. klreed@bu.edu
Stucchi
Arthur F
AF
Leeman
Susan E
SE
Becker
James M
JM
D000818:Animals; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology; D020782:Matrix Metalloproteinases / Q000378:metabolism; D008954:Models, Biological; D064729:Neurokinin-1 Receptor Antagonists; D018384:Oxidative Stress; D010529:Peritoneal Cavity / Q000473:pathology; D010532:Peritoneal Diseases / Q000517:prevention & control*; D011183:Postoperative Complications / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D051381:Rats; D018040:Receptors, Neurokinin-1 / Q000378:metabolism; D013373:Substance P / Q000378:metabolism; D000267:Tissue Adhesions / Q000517:prevention & control
C480026:6-diphenylmethyl-5-(5-isopropyl-2-methoxybenzylamino)-1-azabicyclo(2.2.2)octane-3-carboxylic acid; D019086:Bridged Bicyclo Compounds, Heterocyclic; D064729:Neurokinin-1 Receptor Antagonists; D018040:Receptors, Neurokinin-1; D013373:Substance P; D020782:Matrix Metalloproteinases